A new meta-analysis published in The Lancet warns that stopping GLP-1 weight-loss medications can lead to a significant metabolic rebound. The study, involving over 3,700 participants, found that discontinuing these drugs results in rapid weight regain, worsening blood sugar control, and increased blood pressure. Researchers advocate for evidence-based discontinuation protocols to sustain therapeutic benefits, highlighting the need for long-term maintenance strategies alongside initiation and titration guidelines for these widely used diabetes and obesity medications.